AU760964B2 - 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activityand for use in cancer chemotherapy - Google Patents

3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activityand for use in cancer chemotherapy Download PDF

Info

Publication number
AU760964B2
AU760964B2 AU22215/00A AU2221500A AU760964B2 AU 760964 B2 AU760964 B2 AU 760964B2 AU 22215/00 A AU22215/00 A AU 22215/00A AU 2221500 A AU2221500 A AU 2221500A AU 760964 B2 AU760964 B2 AU 760964B2
Authority
AU
Australia
Prior art keywords
cancer
well
cells
indolinone
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU22215/00A
Other languages
English (en)
Other versions
AU2221500A (en
Inventor
Peter J. Langecker
Laura Kay Shawver
Li Sun
Peng Cho Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sugen LLC
Original Assignee
Sugen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen LLC filed Critical Sugen LLC
Publication of AU2221500A publication Critical patent/AU2221500A/en
Application granted granted Critical
Publication of AU760964B2 publication Critical patent/AU760964B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
AU22215/00A 1998-12-31 1999-12-30 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activityand for use in cancer chemotherapy Ceased AU760964B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11431398P 1998-12-31 1998-12-31
US60/114313 1998-12-31
PCT/US1999/031232 WO2000038519A1 (en) 1998-12-31 1999-12-30 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy

Publications (2)

Publication Number Publication Date
AU2221500A AU2221500A (en) 2000-07-31
AU760964B2 true AU760964B2 (en) 2003-05-22

Family

ID=22354480

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22215/00A Ceased AU760964B2 (en) 1998-12-31 1999-12-30 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activityand for use in cancer chemotherapy

Country Status (10)

Country Link
EP (1) EP1139754A4 (es)
JP (1) JP2002533360A (es)
KR (1) KR20010108063A (es)
CN (1) CN1356872A (es)
AU (1) AU760964B2 (es)
BR (1) BR9916735A (es)
CA (1) CA2357042A1 (es)
IL (1) IL143920A0 (es)
MX (1) MXPA01006742A (es)
WO (1) WO2000038519A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
PT1233943E (pt) * 1999-11-24 2011-09-01 Sugen Inc Formulações para agentes farmacêuticos ionizáveis como ácidos livres ou bases livres
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
NZ520640A (en) * 2000-02-15 2005-04-29 Upjohn Co Pyrrole substituted 2-indolinone protein kinase inhibitors
PL363110A1 (en) * 2000-02-28 2004-11-15 Aventis Pharma S.A. A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
TWI270545B (en) 2000-05-24 2007-01-11 Sugen Inc Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
CA2410509A1 (en) 2000-06-02 2001-12-13 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
BRPI0207961B8 (pt) 2001-03-14 2021-05-25 Bristol Myers Squibb Co uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
AU2002303892A1 (en) 2001-05-30 2002-12-09 Jingrong Cui 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
AR038957A1 (es) * 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
WO2003035619A1 (en) * 2001-10-25 2003-05-01 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003035616A2 (en) * 2001-10-25 2003-05-01 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003035614A2 (en) * 2001-10-25 2003-05-01 Merck & Co., Inc. Tyrosine kinase inhibitors
MXPA04004804A (es) * 2001-11-21 2005-02-17 Sugen Inc Formulaciones farmaceuticas que comprenden derivados de indolinona.
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
RU2316554C2 (ru) 2001-12-27 2008-02-10 Тереванс, Инк. Производные индолина, используемые как ингибиторы протеинкиназы
EP1515680A4 (en) * 2002-06-25 2005-09-21 Wyeth Corp USE OF THIO-OXINDOLE DERIVATIVES IN THE TREATMENT OF SKIN DISORDERS
BR0312054A (pt) * 2002-06-25 2005-10-18 Wyeth Corp Uso de derivados de tio-oxindol na preparação de medicamentos úteis no tratamento de condições relacionadas com hormÈnio, e kit farmacêutico
BRPI0313165B8 (pt) 2002-08-02 2021-05-25 Ab Science 2-(3-aminoaril)amino-4-aril-tiazóis e sua utilização como inibidores de c-kit
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
WO2004045617A1 (en) * 2002-11-15 2004-06-03 Warner-Lambert Company Llc Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
PL1684750T3 (pl) 2003-10-23 2010-10-29 Ab Science 2-Aminoarylooksazole jako inhibitory kinazy tyrozynowej
CN100432071C (zh) * 2004-11-05 2008-11-12 中国科学院上海药物研究所 取代1h－吲哚－2－酮类化合物及其制备方法和用途
CA2603826C (en) 2005-04-04 2013-03-12 Ab Science Substituted oxazole derivatives and their use as tyrosine kinase inhibitors
US8246966B2 (en) 2006-08-07 2012-08-21 University Of Georgia Research Foundation, Inc. Trypanosome microsome system and uses thereof
WO2008066755A2 (en) 2006-11-22 2008-06-05 University Of Georgia Research Foundation, Inc. Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents
PT2780011T (pt) * 2011-11-11 2018-05-14 Lilly Co Eli Terapia de combinação para cancro do ovário
JP7041515B2 (ja) 2015-01-08 2022-03-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 骨、骨髄、及び軟骨の誘導を提供する因子及び細胞
MD3288940T2 (ro) 2015-04-29 2021-08-31 Janssen Pharmaceutica Nv Azabenzimidazoli și utilizarea lor ca modulatori ai receptorilor AMPA
CN105585558A (zh) * 2015-12-15 2016-05-18 贵州大学 双烷氧基嘧啶拼接3-烯键氧化吲哚衍生物及其制备方法及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040116A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Indolinone compounds for the treatment of disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2264220A1 (en) * 1996-08-23 1998-02-26 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040116A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Indolinone compounds for the treatment of disease
US5792783A (en) * 1995-06-07 1998-08-11 Sugen, Inc. 3-heteroaryl-2-indolinone compounds for the treatment of disease
US5886020A (en) * 1995-06-07 1999-03-23 Sugen, Inc. 3-(4'-dimethylaminobenzylidenyl)-2-indolinone and analogues thereof for the treatment of disease

Also Published As

Publication number Publication date
BR9916735A (pt) 2001-09-25
AU2221500A (en) 2000-07-31
KR20010108063A (ko) 2001-12-07
WO2000038519A1 (en) 2000-07-06
EP1139754A1 (en) 2001-10-10
EP1139754A4 (en) 2002-12-18
MXPA01006742A (es) 2004-04-21
CN1356872A (zh) 2002-07-03
CA2357042A1 (en) 2000-07-06
IL143920A0 (en) 2002-04-21
JP2002533360A (ja) 2002-10-08

Similar Documents

Publication Publication Date Title
AU760964B2 (en) 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activityand for use in cancer chemotherapy
US6329375B1 (en) Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
EP2020408B1 (en) Pyrrole substituted 2-indolinone protein kinase inhibitor
EP0984930B1 (en) 2-indolinone derivatives as modulators of protein kinase activity
US6683082B2 (en) Bicyclic protein kinase inhibitors
US6642251B1 (en) Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
US6316635B1 (en) 2-indolinone derivatives as modulators of protein kinase activity
US6849641B1 (en) Azaindole tyrosine kinase inhibitors
EP1259234B9 (en) 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
US20030069421A1 (en) 3-(Piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
US6579897B2 (en) 3-(cycloalkanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
US6130238A (en) 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
US6569868B2 (en) 2-indolinone derivatives as modulators of protein kinase activity
US20030191162A1 (en) 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
US20030073837A1 (en) 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
MXPA00011770A (es) Inhibidores de cinasas de proteina de 2-indolinona sustituida por pirrol

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)